Abbott
abbott.comTotal trials
1,202
Active
86
Phase 3
205
Total enrollment
808,898
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dydrogesterone | — | — | — | — | 2 | ||
| Non-Vitamin K Oral Antagonists | — | — | — | — | — | 1 |
Next readouts
- 2026-06-30
- 2029-01
Top conditions
- Heart Failure89
- Coronary Artery Disease72
- Atrial Fibrillation35
- Rheumatoid Arthritis33
- Coronary Disease28
- Bradycardia25
- Diabetes Mellitus24
- Coronary Restenosis23
Frequently asked questions about Abbott
- How many clinical trials does Abbott have on ClinicalTrials.gov?
- Abbott is listed as the lead sponsor on 1,202 clinical trials in ClinicalTrials.gov, 86 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Abbott's trials are in Phase 3?
- 205 of Abbott's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Abbott focus on?
- Abbott's most-studied conditions on ClinicalTrials.gov are Heart Failure, Coronary Artery Disease, Atrial Fibrillation, Rheumatoid Arthritis, Coronary Disease.
- When are Abbott's next clinical trial readouts?
- Abbott has 2 upcoming primary-completion readouts tracked here; the soonest is “Study of the Effectiveness of Dydrogesterone in the Treatment of Endometriosis-related Pain”, expected around 2026-06-30.